Novo Nordisk A/S (NVO) Balance Sheet

The sequential growth from $559.2B in 2026Q1 to $594.9B in 2026Q2, as reported in financial statements, reflects a continued expansion of the asset base, with PPE increasing by $11.8B in a single quarter. This suggests management is investing heavily in manufacturing capabilities to support future product demand, though the deceleration in revenue growth may indicate that this expansion is anticipatory rather than current. The balance sheet is strengthening in absolute terms, but the rapid asset growth without proportional revenue growth could pressure returns on assets in the near term.

The D/E ratio has more than doubled over the past two years, from 0.27 in 2024Q1 to 0.63 in 2026Q2, based on financial statements, reflecting a strategic shift toward leverage to fund capital expenditures and potential acquisitions. While the absolute level remains moderate compared to peers like Eli Lilly (D/E 1.60), the upward trajectory warrants monitoring. The increase in debt appears deliberate, given the simultaneous rise in cash reserves to $44.5B, suggesting a buffer against refinancing risk, but investors should watch interest coverage as debt service costs grow.

The dramatic reduction in goodwill from $106.6B in 2025Q3 to $19.9B in 2026Q2, as reported in financial statements, suggests a major divestiture or impairment, though the exact cause is not disclosed. This shift reduces intangible asset risk and increases the tangible asset base, which may enhance balance sheet transparency. The heavy investment in PPE, up 43% year-over-year, indicates a capital-intensive expansion strategy, likely to support production of GLP-1 therapies. However, the rapid depreciation and maintenance costs associated with such a large asset base could pressure future margins.

Retained earnings have grown consistently, from $99.0B in 2024Q1 to $224.2B in 2026Q2, based on reported figures, indicating robust profitability and a policy of reinvesting earnings. The equity base is solid, with no evidence of dilution from stock-based compensation, as SBC is reported as zero across all quarters. This suggests that equity growth is organic, driven by net income retention, which enhances the quality of the equity cushion. However, the rapid increase in equity may also reflect the impact of the large acquisition in 2024Q4, which temporarily inflated goodwill and equity, but the subsequent goodwill reduction has normalized the balance sheet.

The cash position jumped from $21.1B in 2026Q1 to $44.5B in 2026Q2, as per financial statements, providing a substantial liquidity buffer against operational shocks. However, the current ratio remains below 1.0 at 0.87, suggesting that current liabilities exceed current assets, which could indicate reliance on short-term financing or efficient working capital management. The improvement from 0.79 in the prior quarter is positive, but investors should monitor whether the company can maintain adequate liquidity as it continues to invest heavily in capex and service its growing debt load.